Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells 15,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director John Johnson sold 15,000 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $91,350.00. Following the completion of the transaction, the director directly owned 683,083 shares in the company, valued at approximately $4,159,975.47. This represents a 2.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Price Performance

Shares of XERS stock traded up $0.03 during trading hours on Friday, hitting $6.18. 1,028,207 shares of the company’s stock were exchanged, compared to its average volume of 1,829,779. Xeris Biopharma Holdings, Inc. has a 52 week low of $4.30 and a 52 week high of $10.08. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of 103.00 and a beta of 0.78. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50. The stock’s 50-day moving average is $6.08 and its 200-day moving average is $6.60.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. As a group, research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on XERS. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a research report on Monday, March 2nd. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.80.

Institutional Investors Weigh In On Xeris Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its holdings in Xeris Biopharma by 21.8% in the first quarter. Bank of America Corp DE now owns 874,397 shares of the company’s stock valued at $5,072,000 after purchasing an additional 156,483 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Xeris Biopharma by 322.8% during the first quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock worth $1,713,000 after buying an additional 225,602 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Xeris Biopharma by 19.3% during the 1st quarter. California State Teachers Retirement System now owns 180,339 shares of the company’s stock worth $1,046,000 after buying an additional 29,168 shares during the period. Royal Bank of Canada grew its position in shares of Xeris Biopharma by 12.9% during the 1st quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock worth $253,000 after buying an additional 4,974 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Xeris Biopharma by 59.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 72,804 shares of the company’s stock valued at $422,000 after acquiring an additional 27,003 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.